Navigation Links
Data from Phase 2 Study of Alder Biopharmaceuticals' Anti-IL-6 Antibody Therapeutic, ALD518, Demonstrate Reversal of Anemia in Patients with Advanced Non-Small Cell Lung Cancer
Date:12/7/2010

ORLANDO, Fla., Dec. 7, 2010 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced that data from a Phase 2 study of its ALD518 investigational antibody therapeutic that targets interleukin-6 (IL-6) demonstrate a reversal of anemia in patients with advanced non-small cell lung cancer (NSCLC).

After 12 weeks of treatment with the anti-inflammatory therapeutic, 58 percent of patients who received ALD518 experienced hemoglobin level increases from less than 11 g/dL to more than 12 g/dL, while no patients receiving placebo experienced this increase. In addition, patients who received ALD518 had an average lean body mass loss of 0.19 kg, compared to an average loss of 1.5 kg in those who received placebo. Additional symptoms of the disease such as fatigue were also reduced in patients who received ALD518.

The data was presented by Michael Schuster, M.D., director of the hematologic malignancy program at Stony Brook University Medical Center, at the annual meeting of the American Society of Hematology. The presentation, titled "Inhibition of Interleukin-6 (IL-6) Reverses Anemia In Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial," took place on Monday, December 6.

"The anemia of chronic disease that is seen in cancer patients is in large part due to IL-6 stimulation of hepcidin, resulting in reduced plasma iron levels," said Dr. Schuster. "Given the recent safety concerns over the use of ESAs, alternative therapeutic approaches that target IL-6, such as ALD518, would be very desirable and could potentially reduce the requirement for transfusions in this patient population."

Randall Schatzman, Ph.D., president and chief executive officer of Alder Biopharmaceuticals, added, "We continue to be encouraged by strong clinical data from ALD518 in the areas of cancer, cancer supportive care and cancer anemia. We look forward to continuing our clinical investig
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... TORONTO , May 4, 2015 ... that it intends to dividend to its stockholders a ... a definitive licensing agreement to license its RapidMist™ buccal ... (OTCQB:SMFI). As announced on April 23, 2015, ... respect of the licensing of its RapidMist™ buccal drug ...
(Date:5/4/2015)... , May 4, 2015 RadiologyAuction will have ... live video and product demonstrations at the end of ... equipment such as Kodak and Fuji Cr,s, Agfa and ... at the first event. Various imaging equipment will be ... . After years of buying and selling ...
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5RadiologyAuction Announces Event Starting On May 5th 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3
... CITY, Minn., Dec. 21 William Fals-Stewart,Ph.D., professor in ... in,Rochester, New York, has earned the 2007 Dan Anderson ... partner involvement in the,treatment of female alcoholics. Sponsored by ... a single published article by a researcher,who has advanced ...
... Dec. 20 Novavax, Inc.,(Nasdaq: NVAX ) ... I/IIa,human clinical trial of its non-adjuvanted pandemic influenza ... Chief Medical Officer and Head of Clinical,Development stated, ... are,promising and support further development of our pandemic ...
Cached Medicine Technology:Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 2Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 3Fals-Stewart Earns Hazelden's 2007 Dan Anderson Research Award 4Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 2Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 3Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program 4
(Date:5/4/2015)... Each year, the Susan G. Komen organization ... awareness for breast cancer. This year, Dr. Mark Deutsch and ... the entertainment sponsor for the 25th annual Susan G. Komen ... the Lenox Square Mall. , The Komen organization hopes have ... $1.2 million. Perimeter Plastic Surgery has not only taken on ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Getting patients ... manage their health is critical to achieving the “triple ... reducing costs, but this will require a shift in ... also demands that health systems move beyond their traditional ... took part in the third live meeting of the ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “ LiveSchool ... monthly AppWatch, which takes a look at the latest ... and Windows. Joe Toohey, the host of AppWatch and ... viewers how this application allows teachers to reward students ... than some realize, especially in the classroom. And ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – the ... lymphoma research and serving the lymphoma community through a ... services – is set to host its annual Ace ... Orange, NJ on June 1, 2015. Since 2010, the ... through LRF. , This year, the Lymphoma Research Foundation ...
(Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
Breaking Medicine News(10 mins):Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
... 8, 2007 -- Results from two investigational Phase I ... preliminary anti-tumor activity in patients with relapsed and/or refractory ... 10 of 21 (48 percent) evaluable patients had a ... combination treatment. Data from a second study, sponsored ...
... Boca Raton, FL, December 8, 2007 Researchers may ... almost immediately by directly targeting novel molecules in the ... can lead to longer times for medication to take ... American College of Neuropsychopharmacology (ACNP) annual meeting. The antidepressant ...
... Elderly may be especially prone to depression this time of ... For some older people, the holidays can generate feelings of ... or health problems, experts note. , To help seniors ... offers the following tips: , Socialize. Ask family and ...
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... Company that it will evaluate the,approval of potential anti-arrhythmic ... ongoing review of the Company,s,supplemental new drug application (sNDA)., ... seeking expansion to the,approved product labeling for Ranexa to ...
... Legendary blues artists Bobby,Rush and James "Super Chikan" Johnson ... Blues Marathon and Half-Marathon on Saturday,January 5, 2008. The ... at 200,South Commerce Street, in downtown Jackson. Doors will ... on stage at 8:00 p.m., and the Bobby Rush,Revue ...
... Ala., Dec. 7 BioHorizons Implant Systems,Inc. ... to a,state-of-the- art, 44,000 square foot facility. ... houses all administrative services, a newly,formed manufacturing ... will include machining, surface treatment and packaging ...
Cached Medicine News:Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 2Health News:ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity 3Health News:Study shows new strategy for developing antidepressants 2Health News:Study shows new strategy for developing antidepressants 3Health News:How to Spot, and Beat, the Holiday Blues 2Health News:FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R) 2Health News:FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R) 3Health News:BioHorizons Expands to New 44,000 Square Foot Facility 2
... acuity system allows you access to the ... The system includes 10 different optotypes, crowding ... animated characters. Random character sequencing eliminates memorization. ... single line and multiple line selection capability. ...
... Light Probes provide the surgeon with an ... interface to be easily visualized through the ... effect and light scatter technique, the surgeon ... deposits, flap edge folds, corneal flap striae ...
... visual acuity system allows you access to ... II. The system includes 10 different optotypes, ... and animated characters. Random character sequencing eliminates ... letter, single line and multiple line selection ...
... to 64 channel sleep diagnostic collection software. ... 64 channel sleep diagnostic collection software offers ... recording or post recording. The scoring displays ... sleep events including current number of events, ...
Medicine Products: